Q1 2019 EPS Estimates for Synlogic Inc (SYBX) Decreased by Analyst
Synlogic Inc (NASDAQ:SYBX) – Research analysts at Wedbush decreased their Q1 2019 earnings per share (EPS) estimates for Synlogic in a research report issued on Wednesday, March 13th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($0.49) per share for the quarter, down from their prior forecast of ($0.48). Wedbush also issued estimates for Synlogic’s Q2 2019 earnings at ($0.49) EPS, Q3 2019 earnings at ($0.42) EPS, Q4 2019 earnings at ($0.42) EPS, FY2019 earnings at ($1.83) EPS, FY2021 earnings at ($1.64) EPS and FY2022 earnings at ($1.11) EPS.
Other equities analysts have also recently issued reports about the company. Chardan Capital initiated coverage on Synlogic in a research note on Thursday, December 13th. They set a “buy” rating and a $20.00 target price for the company. ValuEngine upgraded Synlogic from a “hold” rating to a “buy” rating in a research note on Tuesday, December 11th. HC Wainwright set a $20.00 target price on Synlogic and gave the company a “buy” rating in a research note on Monday, December 10th. Zacks Investment Research upgraded Synlogic from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Friday. Finally, BTIG Research initiated coverage on Synlogic in a research note on Tuesday, February 12th. They set a “buy” rating and a $22.00 target price for the company. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $18.47.
Synlogic (NASDAQ:SYBX) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.09. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.24 million. Synlogic had a negative return on equity of 35.58% and a negative net margin of 1,922.02%.
In related news, insider Paul Francis Miller sold 9,000 shares of the firm’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $9.75, for a total transaction of $87,750.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 23.30% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in SYBX. NEA Management Company LLC bought a new position in Synlogic during the third quarter worth $60,100,000. Aquilo Capital Management LLC bought a new position in Synlogic during the third quarter worth $14,182,000. BlackRock Inc. bought a new position in Synlogic during the third quarter worth $13,301,000. Vanguard Group Inc bought a new position in Synlogic during the third quarter worth $9,958,000. Finally, Vanguard Group Inc. bought a new position in Synlogic during the third quarter worth $9,958,000. Hedge funds and other institutional investors own 84.85% of the company’s stock.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Read More: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.